Literature DB >> 16609368

Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype.

Zhengwen Jiang1, Nadine Dragin, Lucia F Jorge-Nebert, Martha V Martin, F Peter Guengerich, Eleni Aklillu, Magnus Ingelman-Sundberg, George J Hammons, Beverly D Lyn-Cook, Fred F Kadlubar, Shannon N Saldana, Michael Sorter, Alexander A Vinks, Nassr Nassr, Oliver von Richter, Li Jin, Daniel W Nebert.   

Abstract

The genotype responsible for more than 60-fold interindividual differences in human hepatic CYP1A2 constitutive expression is not understood. Resequencing the human CYP1A1_CYP1A2 locus (39.6 kb) in five major geographically isolated subgroups recently led to the identification of 85 single nucleotide polymorphisms (SNPs), 57 of which were double-hit SNPs. Here, we attempted to correlate the CYP1A2 genotype with a metabolic phenotype. We chose 16 SNPs (all having a minor allele frequency > or =0.05 in Caucasians) to genotype 32 DNA samples (26 Caucasians, six Ethiopians) in which CYP1A2 metabolism had previously been determined. From 280 subjects (five locations worldwide) that had been CYP1A2-phenotyped, we genotyped the 10 highest, 14 lowest and eight intermediate DNA samples. Although no SNP was significant (P<0.05), possibly due to the small sample size, we found a trend for several of the six SNPs across the CYP1A2 linkage disequilibrium block associated with the trait. Five CYP1A2 haplotypes were inferred, two of which had not previously been reported; haplotype 1A2H10 showed the greatest association with CYP1A2 activity. Regulatory sequences responsible for the large interindividual differences in hepatic CYP1A2 gene basal expression might reside, in part, with some of these CYP1A2 SNPS but, in large part, might be located either cis (in nearby sequences not yet haplotyped) or trans in that they are not linked to the gene. We conclude that no SNP or haplotype in the CYP1A2 gene has yet been identified that can unequivocally be used to predict the metabolic phenotype in any individual patient.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16609368     DOI: 10.1097/01.fpc.0000204994.99429.46

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  27 in total

1.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Authors:  Roza Ghotbi; Magnus Christensen; Hyung-Keun Roh; Magnus Ingelman-Sundberg; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2007-03-17       Impact factor: 2.953

Review 2.  Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.

Authors:  P K Gillman
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

Review 3.  From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions.

Authors:  Daniel W Nebert; Ge Zhang; Elliot S Vesell
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

Review 4.  Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment.

Authors:  Cristina Rodriguez-Antona; Alvin Gomez; Maria Karlgren; Sarah C Sim; Magnus Ingelman-Sundberg
Journal:  Hum Genet       Date:  2009-10-08       Impact factor: 4.132

5.  CYP1A2, GSTM1, and GSTT1 polymorphisms and diet effects on CYP1A2 activity in a crossover feeding trial.

Authors:  Sabrina Peterson; Yvonne Schwarz; Shuying S Li; Lin Li; Irena B King; Chu Chen; David L Eaton; John D Potter; Johanna W Lampe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-20       Impact factor: 4.254

6.  Heterocyclic amine intake, smoking, cytochrome P450 1A2 and N-acetylation phenotypes, and risk of colorectal adenoma in a multiethnic population.

Authors:  Jenna Voutsinas; Lynne R Wilkens; Adrian Franke; Thomas M Vogt; Lance A Yokochi; Robert Decker; Loïc Le Marchand
Journal:  Gut       Date:  2012-05-24       Impact factor: 23.059

Review 7.  Blood pressure in relation to coffee and caffeine consumption.

Authors:  Idris Guessous; Chin B Eap; Murielle Bochud
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

8.  Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study.

Authors:  Li Tao; Yong-Bing Xiang; Kenneth K Chan; Renwei Wang; Yu-Tang Gao; Mimi C Yu; Jian-Min Yuan
Journal:  Int J Cancer       Date:  2011-06-21       Impact factor: 7.396

9.  CYP1A1/2 haplotypes and lung cancer and assessment of confounding by population stratification.

Authors:  Melinda C Aldrich; Steve Selvin; Helen M Hansen; Lisa F Barcellos; Margaret R Wrensch; Jennette D Sison; Karl T Kelsey; Patricia A Buffler; Charles P Quesenberry; Michael F Seldin; John K Wiencke
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

10.  Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats.

Authors:  Ans Punt; Alicia Paini; Marelle G Boersma; Andreas P Freidig; Thierry Delatour; Gabriele Scholz; Benoît Schilter; Peter J van Bladeren; Ivonne M C M Rietjens
Journal:  Toxicol Sci       Date:  2009-05-15       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.